الفهرس 
Outcome and prognostic factors of pediatric patients with hodgkin’s lymphoma : single center experience
List of AbbreviationsOnly 14 pages are availabe for public view
 |  | from | 187 |  |  |
| | | from | 187 | | |
Abstract
Background:
Hodgkin’s lymphoma (HL) is a highly curable malignant disease. Risk adapted
therapy for children with HL is directed toward high survival, minimal toxicity and
optimal quality of life.
Purpose: To estimate overall survival (OS) and Event free survival (EFS) of
Hodgkin’s lymphoma pediatric patients treated at National Cancer Institute (NCI),
Cairo University, Egypt.
Methods: This is a retrospective study that included all newly diagnosed Classic
Hodgkin’s lymphoma pediatric patients treated at National Cancer Institute (NCI),
Cairo University (CU) between January 2016 till December 2018.
Results: In 69 eligible patients, median age was 8 years (range 3 – 17 years). Male
to female ratio of 4.7:1. Cervical lymphadenopathy was the commonest
presentation (43%). Most cases had nodular sclerosis histologic subtype (33 cases; 47.8%). Elevates ESR (>50) was found in 18%, 42% had ≥3 LN affection, 11%
had bulky mediastinal disease, B-symptoms was present in 34% of patients. The
majority of patients received chemotherapy alone 47 patients (68%), while 22
patients (31%) received combined modality treatment (CMT). 3y OS & EFS in
patients receiving CMT was 95.5% & 87.6% vs 89.9% & 83.3% in patients
receiving chemotherapy alone (P= 0.72 & 0.909). Patients with Interim negative
had a 3y OS & EFS (94.7% & 84.8%) vs (74.1% & 74.1%) in patients with interim
positive (P= 0.068 & 0.351). Patients with negative interim PET who received
CMT had 3y OS & EFS of (100% & 88.2%) vs (95% & 90%) in patients receiving
chemotherapy alone (P= 0.35 & 0.719). At the end of the study, EFS and OS was
(83% and 91.9%) respectively. Nine cases had positive interim PET and had a
significantly lower EFS and OS than the cases with negative interim PET (74.1%
and 74.1%) vs (84.8% and 94.7%) Conclusion: Age >15 years, B-symptoms, ≥3 involved LN groups, and stage were
significant pretreatment predictors of outcome, Risk and response adaptive
treatment is the standard of care for treating pediatric patients with Hodgkin
lymphoma, PET/CT is the standard tool for diagnosis and response assessment in
HL.